Abstract 726P
Background
Patients with recurrent cervical cancer, especially those resistant to platinum-based chemotherapy, have limited treatment options. PD-1 blockade monotherapy stands out as one of the optimal choices in this context. PARP inhibition may exert an immune modulatory effect through the cGAS/STING pathway, and this phase II trial aims to explore the efficacy and safety of pembrolizumab (Pem) plus olaparib (Ola) in this patient cohort.
Methods
This multicenter investigator-initiated single-arm Phase II trial assesses the antitumor effects and survival outcomes of combining PD-1 inhibition with Pem and PARP inhibition with Ola. Eligible patients, who had prior platinum-based chemotherapies and no prior immunotherapy, received Pem (200mg every 3 weeks) and Ola (600mg per day) combination therapy until disease progression or unacceptable toxicity. The primary endpoint is objective response rate (ORR) by RECISTv1.1.
Results
Between June 2021 and July 2022, twenty-eight patients were enrolled. Patient characteristics included a median age of 55 years, with 14 (50%) patients having squamous cell carcinoma and 14 (50%) adenocarcinoma/adenosquamous carcinoma. Twenty-two (79%) patients had more than 2 lines of chemotherapy, and 22 (79%) patients had a history of bevacizumab. Twenty-six of 28 patients were evaluable for antitumor activity, as two patients did not have RECIST evaluation after treatment initiation. The ORR was 7.7% and the disease control rate was 53.8%. The median PFS and OS were 3.4 and 11.9 months, respectively. No patients required Pem discontinuation, but 4 (14%) patients required Ola discontinuation due to adverse events (AEs). All patients and 21 (75%) patients experienced any grade of AEs due to Ola or Pem, respectively. Grade≥3 AEs were observed in 17 (61%) patients, with anemia (29%) and decreased white blood cell counts (11%) being the most common.
Conclusions
This trial investigates Pem plus Ola combination therapy in platinum-experienced recurrent cervical cancer, revealing manageable safety. However, limited activity was observed with the addition of Ola to PD-1 inhibition in this study.
Clinical trial identification
NCT04641728. First posted November 24, 2020.
Editorial acknowledgement
Legal entity responsible for the study
Gynecologic Oncology Trial and Investigation Consortium (GOTIC).
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
630P - Debio 0123 + carboplatin (CP) for patients (pts) with advanced solid tumors: Safety, preliminary efficacy and determination of recommended phase II dose (RP2D)
Presenter: Hans Gelderblom
Session: Poster session 01
631P - Phase Ib expansion study of CX-5461 in patients with solid tumours and BRCA2 and/or PALB2 mutation
Presenter: Pamela Soberanis Pina
Session: Poster session 01
632P - Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors
Presenter: Chia-Chi Lin
Session: Poster session 01
633P - First-in-human dose-escalation study of basroparib (STP1002) in patients with advanced-stage solid tumors
Presenter: Christopher Lieu
Session: Poster session 01
634P - First results from phase I/II study of CTS2190, a novel small-molecule inhibitor of type I PRMTs, in patients with advanced solid tumors
Presenter: Xiangdong Cheng
Session: Poster session 01
635P - The phase I dose-escalation study of TSN084, a multi-kinase inhibitor, in patients with advanced malignant tumors
Presenter: Jie Wang
Session: Poster session 01
636P - Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplification: A molecular screening and therapeutics (MoST) program substudy
Presenter: Benjamin Kong
Session: Poster session 01
637P - AC699, a novel chimeric estrogen receptor degrader, in a phase I study in breast cancer
Presenter: Erika Hamilton
Session: Poster session 01
638P - Final results of IMPACT 2, a randomized study evaluating molecular profiling and targeted agents in metastatic cancer at MD Anderson Cancer Center
Presenter: Apostolia Maria Tsimberidou
Session: Poster session 01
639P - Serial ctDNA profiling as a catalyst for tailored therapeutics in advanced cancer: Analysis of two precision medicine studies
Presenter: Sophie Cousin
Session: Poster session 01